





Background: Skin cancer is a major public health burden.  While treatable, early diagnosis 
usually portends a better prognosis.  Screening is one preventive measure, although the United 
States Preventive Services Task Force has deemed there to be “insufficient evidence” for 
recommendation.  The American Academy of Dermatology has sponsored free, public skin 
screenings since 1985, but there is minimal data supporting these efforts.  The utility of 
community screening events in general is debated in the literature. 
Objective: To determine whether free, public skin cancer screenings are effective for secondary 
prevention of skin cancer through an analysis of follow-up rates of screening events hosted by 
the Polka Dot Mama Melanoma Foundation.  To explore the challenges of implementing and 
measuring effectiveness of a community screening event. 
Methods: I conducted an observational study using survey data, along with a literature review 
on the value of community-oriented screening events. 
Results: Most screening participants were white, female, and 51 to 65 years old.  More than half 
have had at least one blistering sunburn before age 20 years old and approximately half have 
used indoor tanning equipment.  Over half of participants surveyed by telephone reported 
demonstrating sun-protective behaviors since their screening.  Approximately one-third of 
participants had never seen a dermatologist prior to the screening.  Diagnostic confirmation of 
four total skin cancers and two precancerous AKs appeared to result from these screening events. 
Conclusion: Community screenings are primarily helpful insofar as their success can be 
measured.  It is important to study challenges associated with community screenings for the 
evaluation and success of future community screening events.  The general sentiment toward 




screenings have a positive influence on the community and save lives. 
 
Acknowledgements 
I want to thank Dr. Sue Tolleson-Rinehart for her tireless support throughout my 
practicum and master’s paper writing experiences, and for her encouragement throughout my 
year at the Gillings School of Public Health.  I thank Dr. Adewole Adamson for his research and 
career mentorship in dermatology, as well as his guidance in completing this project.  I also 
thank Tracy Callahan, Founder and Chief Executive Officer of the PDMMF, for her support 
throughout all aspects of my practicum.  I thank Drs. Heather Lampel and Elizabeth Ju for their 
clinical dermatology content expertise and career advice.  I thank the following dermatology 
providers for volunteering their time to screening events: Dr. Elizabeth Ju, Dr. Vikas Patel, Dr. 
Health Lampel, Dr. David Kowalski, Dr. David Dasher and Dr. Stephanie Carstens, Leighanne 
McGill, PA-C, and Karlee Wagoner, NP.  Finally, I thank Nakisa Sadeghi for her help with 
follow-up data collection. 
  
 
Table of Contents 
List of Tables………………………………………………………………………...1 
List of Figures………………………………………………………………………..1 
List of Abbreviations………………………………………………………………...2 
Introduction, Background & Significance…………………………………………...3 
Methods……………………………………………………………………………...8 
Results……………………………………………………………………………….10 
Discussion & Conclusions…………………………………………………………..12 
References…………………………………………………………………………...19 
Figures & Tables………………………………………………………………….....23 
Appendix I: Methods, results, surveys, & screening information…………………..31 
Appendix II: Limited systematic review……………………………………………44 
List of Tables 
Table 1: Skin screening demographics………………………………………….….26 
Table 2: Sun-protective behaviors………………………………………………….27 
Table 3: In-person survey results…………………………………………………..28 
Table 4: Telephone follow-up survey results………………………………………29 
Table 5: Skin screening results……………………………………….……………30 
List of Figures 
Figure 1: Skin screening events…………………………………………………....23 
Figure 2: Presumptive diagnoses…………………………………………….…….24 





List of Abbreviations 
AAD  American Academy of Dermatology  
AK  Actinic keratosis  
BCC  Basal cell carcinoma  
CN  Congenital nevus 
DLC  Dermatology and Laser Center of Chapel Hill 
DN  Dysplastic nevus 
MMS Mohs micrographic surgery 
NCDA North Carolina Dermatology Associates 
NOS  Not otherwise specified 
PDMMF Polka Dot Mama Melanoma Foundation 
SCC  Squamous cell carcinoma 
SK  Seborrheic keratosis 
USPSTF United States Preventive Services Task Force 
US  United States 


















Introduction, Background & Significance 
Burden of skin cancer 
 Skin cancer, including melanoma and non-melanoma, is a serious public health concern.  It 
is the most common type of cancer with over 95,000 estimated new cases in the US each year 
(Facts & Figures, 2017).  Approximately 5 million total cases are diagnosed annually and by 65 
years old, ~50% of all Americans will develop one of these cancers (Holland, 2014; Key 
Statistics, 2018).  Non-melanoma skin cancer (BCCs and SCCs) is the most common form of 
skin cancer, but melanoma is the deadliest (Key Statistics, 2018).  In 2014, there were 2.8 to 3.0 
deaths per 100,000 people from melanoma and the past 30 years have shown increasing rates of 
melanoma (Rates by State, 2017).  The American Cancer Society estimates that approximately 
9,320 people will die of melanoma in the U.S. in 2018 (About Melanoma. 2016). Caucasians, 
especially males over 50 years old, are at highest risk for developing skin cancers (Holland, 
2014). 
 Treatment choice for skin cancer depends on various tumor characteristics (type, size, 
location, depth), patient age and overall health status (Treatment Options, 2018).  Treatment of 
early-stage lesions usually occurs as an outpatient procedure and causes little pain or discomfort.  
Options include simple excision, electrosurgical, cryosurgery, radiation, lasers, topical 
medication, or photodynamic therapy (About Melanoma, 2016).  Although MMS has also been 
used successfully to treat both in situ and invasive cutaneous melanoma, standard of care and 
recommended treatment is wide local excision (Degesys, Powell, Hsia & Merritt, 2018).  See the 
limited systematic review in Appendix II on evaluation of the effectiveness of Mohs 




Although some forms are more aggressive than others, skin cancer is common with a 
potentially fatal outcome.  As skin cancer incidence increases with age and years of exposure to 
the sun and although it can be deadly, early detection portends a higher chance of survival 
(Survival Rates, 2016).  An attempt to detect skin cancer early, through screening and other 
efforts, is important to avoid local and possibly distant metastatic invasion.  Barriers to diagnosis 
and treatment of skin cancer often involve access to skin screening services by a dermatologist, 
low patient health literacy, education, and awareness about skin cancer (Treatment Options, 
2018; About Melanoma, 2016). 
 
Free, public skin screenings 
Approaches to prevention often include a combination of education, awareness, behavior 
modification, and screening efforts (Boulos, 2012; Geller, 2013; Torres, 2017).  The USPSTF, 
however, issues a grade of "I" for "insufficient" evidence to weigh the benefits vs. harms of 
screening adult patients. Minimal literature exists on the effectiveness of free, public screenings 
as measures of secondary prevention of skin cancers (USPSTF, 2015).  
Free public skin screenings have been sponsored and promoted by the AAD for more than 
30 years, since 1985.  The AAD partners with organizations throughout the US to provide 
screenings in various settings to increase access to dermatologic care for persons who would 
otherwise be unscreened (SPOT, 2018).  These screening events are hypothetically useful for 
both early detection and education.  Nevertheless, little evidence exists on rates of skin screening 
follow-up in the US.  Consequently, there is ongoing debate about the intrinsic value of these 
screenings, creating a need for more substantial data on the utility of screening events for 




Prior studies have determined the majority of screening participants to be non-elderly 
Caucasian, well-educated, and insured females over 50 years old (Grant-Kels & Stoff, 2017; 
Stoff & Grant-Kels, 2017).  This study is needed to characterize the population of a collection of 
small-scale screening participants to determine who screenings are reaching and if this is the 
population that should be targeted.  Ultimately, this study will contribute to existing literature on 
the value of skin screenings as a tool to prevent skin cancer, and more generally, community-
based screening events. 
 
Community-oriented screenings 
 The World Health Organization and the US Department of Health and Human Services 
Healthy People Goals for the Nation historically have promoted disease prevention efforts as 
being of utmost importance in health care.  A few viable approaches to disease prevention are 
education, behavior change, and screenings. The concept of community-based screening events 
is not new and is still being investigated in many areas of health care, especially chronic disease 
prevention (Engebretson, Mahoney, & Walker, 2005).  Such community-based events provide 
not only a screening service, but also health-related education and awareness often to low-
income, underinsured populations (Escoffery et al., 2017).  They offer a free opportunity to 
assess individual health risks of developing certain medical conditions, such as diabetes, 
glaucoma, and even skin cancer (McKeirnan, Panther, & Akers, 2015).  Theoretically the goal is 
to create a chance for early diagnosis ultimately to reduce dire outcomes such as mortality 
(Escoffery et al., 2017).   
 Although the idea of screening efforts may seem beneficial, as previously mentioned, their 




Ilesanmi, & Ogunniyan, 2011).  Colorectal, cervical, and breast cancer screenings are well-
studied, as these cancers have known strategies for early detection (Escoffery et al., 2017).  The 
following criteria deem a screening program effective: high burden of disease suffering, good 
screening test, efficacious treatment(s) exists, those who could benefit are actually reached, those 
with positive screening results follow recommendations, and the overall health system has 
sufficient resources to do both the screening and follow-up (Cadman, Chambers, Feldman, & 
Sackett, 1984).   
 Formal evaluation of community screening efforts is scarce.  Most available statistics come 
from studies of the on-site screenings, but there is very limited long-term follow-up data to 
suggest what, if any effect screenings have on important outcomes such as early detection rates 
and mortality (Escoffery et al., 2017).  Additional, more rigorous analyses of skin screening 
efforts, moreover, are lacking.  Past health outcomes and economic analyses have demonstrated 
that diabetes screening programs portend significant health care cost savings (McKeirnan et al., 
2015).  Such thorough investigations have not been performed however, for skin cancer 
screenings.   
 Community screening events, such as those hosted by the PDMMF, are outstanding for 
purposes of subjectively determining skin cancer risk and providing a recommendation for 
follow-up, which the organizers of the screening hope will be acted on. Two other advantages of 
early detection through screenings is long-term potential for significant cost of care reduction 
and improved patient outcomes (McKeirnan et al., 2015). 
 An important consideration is that the effectiveness of community screenings depends to a 
degree on individual proactivity.  Participants must take it upon themselves to arrange follow-up 




do not follow-up are not well understood.  Structured focus group interviews in the setting of a 
semirural community screening, for example, revealed that several interpersonal and 
environmental variables predict active participation in community screening events.  The 
investigators concluded that community settings are good for inspiring a sense of overall 
community-wide support, but, ironically, inhibited turnout because of confidentiality and privacy 
concerns (Engebretson, Mahoney, & Walker, 2005).  Research teams have investigated the many 
discrete events that must occur after screening and their balance of benefits vs. harms.  
Specifically, post-screening events include confirmatory diagnosis, intervention, and follow-up 
but, although these additional steps would be ideal, screenings usually do not include any formal 
continuity of care to ensure they take place (Cadman et al., 1984). 
 Ultimately, screening programs are designed to detect early disease in seemingly healthy 
people (Adebayo et al., 2011).  The Guide to Community Preventive Services offers examples of 
multiple recommended cancer screening initiatives that have worked well for breast, cervical, 
and colorectal screenings.  The Community Guide summarizes systematic reviews to suggest 
evidence-based recommendations for preventing skin cancer.  The recommendation focuses on a 
multicomponent community-wide intervention.  Nowhere in the recommendation is there 
mention of screening (Community-wide interventions, 2016).   
 Given how common and potentially deadly skin cancer can be, many in the public seem 
indifferent to skin health and protection.  Most major conditions appear initially as a small sign 
or symptom, which highlights the importance of preventive health care, particularly through 
screening.  A more formal evaluation of skin cancer screening efforts is needed to determine 






 The purpose of this study is to determine whether free, public skin cancer screenings are an 
effective method for secondary prevention of skin cancer by analyzing follow-up rates of 
screening events hosted by the PDMMF between August 1, 2017 and May 9, 2018.  Another 
main objective is to evaluate community-based screening events from a methodological, 
program-planning, implementation, and outcomes assessment perspective.  
 Secondary objectives include to increase public education and awareness about skin 
cancer, understand public awareness and perception of skin cancer, and learn more about skin 
cancer epidemiology in North Carolina.  This evaluation will primarily help to answer questions 




 This is an observational, quasi-experimental study both cross-sectional and retrospective in 
nature.  This type of study design is simple with no control, one group, and post-test only.  
 
Data collection 
 I collected data from in-person surveys and AAD standardized forms administered 
during the entire nine-month study period between August 1, 2017 and May 9, 2018. Then, 
participants completed a screening skin examination by a local, board-certified dermatologist 
who determined and recorded whether a referral was made. Participants with concerning lesions 
were advised to follow-up with their own dermatologist for further diagnostic and/or treatment 




only for participants screened until March 27, 2018.  Surveys and forms can be found in 
Appendix I (Powell & Tolleson-Rinehart, 2017). 
 
Recruitment, sample and participant selection 
Participants were recruited prior to screening events by word-of-mouth, email, Facebook, 
and online advertisements.  Participants were also recruited by investigators in-person and on-
site the day of screening events.  All participants were attendees at a PDMMF free, public skin 




 The following participant identifiers were collected during screening events: names, birth 
dates, telephone numbers, email addresses, and mailing address.  Other variables were responses 
to in-person and telephone follow-up surveys, as shown in Appendix I. 
 
Statistical analysis 
 I performed statistical analyses using Stata/MP 15.0 (StataCorp, College Station, TX).  
First, I calculated summary statistics for basic demographic information as summarized in Table 
1.  Next, I computed summary statistics for responses to surveys and to describe screening 
follow-up results, as seen in tables and figures in Appendix I. 
 
Other 








 From August 1, 2017 to May 9, 2018, 216 individuals were screened at 17 total screening 
events (Figure 1).  Information about individual screening events can be found in Appendix I.  
Of those who were screened, 81.0% were white, 61.6% were women, and age ranged from 19 to 
70 years (mean 46.53  1.02 years).  People aged 51 to 65 years comprised 32.4% of 
participants, followed by persons aged 36 to 50 years (29.2%).  
 
Risk factors and sun-protective behaviors 
 Participants responded to questions about skin cancer risk factors (Table 2).  Overall, 
10.3% had a personal history of skin cancer, 39.3% reported noticing a recently-changing mole, 
38.7% reported always using sunscreen, 13.4% reported always wearing sun-protective clothing, 
54.3% reported having had 1-3 blistering sunburns before 20 years old, and 50.5% have never 
used indoor tanning equipment.   
 In response to telephone follow-up questions about sun-protective behaviors since their 
screening (Table 4), 73.3% of participants reported using sunscreen (average SPF 36.7  13.5), 
66.7% reported seeking shade, 82.7% reported wearing sun-protective clothing, 77.3% reported 
having had no sunburns or tans, 58.7% reported having performed skin self-exams, and 65.3% 







 In response to an in-person general knowledge question about the most commonly 
diagnosed cancer in the US, 63.8% of participants answered correctly that non-melanoma skin 
cancer is most common, followed by those who thought breast cancer (26.2%) and lung cancer 
(7.1%) were the most common.  During telephone follow-up surveys, 77.3% of participants 
answered correctly, again followed by those who chose breast (18.7%) and lung cancer (4.0%) as 
most common. 
 
Publicity about community screenings 
 Participants primarily obtained information about screenings through email or newsletter 
(28.4%), followed by some other source (19.9%), family or friends (18.4%), and websites 
(13.5%), as shown in Table 3. 
 
Access to care 
 Among participants who completed the in-person survey, 61.0% were women and 31.2% 
reported never having seen a dermatologist (Table 3).  Less than half (34.7%) of total screening 
participants were reached by telephone for follow-up, of which 28.0% reported having seen a 
dermatologist since the screening event.  These results will later be placed in the context of those 
who were screened, referred, and later followed up.   
 
Presumptive screening findings and follow-up 
 Among all screening participants over the study period, 250 total suspicious lesions were 




(38.4%), SK (25.6%), AK (15.6%), DN (8.8%), BCC (3.6%), SCC (2.4%), CN (2.4%), lesion-
NOS (2.4%), and melanoma (0.8%). 
 As seen in Table 5, 75 participants (34.7% of 216 total screened) were contacted 
successfully by telephone for follow-up. During the screening period, 52 total individuals (24.1% 
of total) were referred for biopsy, 12 of whom were reached by telephone for follow-up.  Among 
those contacted, 8 individuals were biopsied. Biopsy-confirmed results obtained based on phone 
calls were as follows: 7 benign lesions, 3 BCCs, 2 AKs, 1 SCC, and 1 DN.   
 
Discussion & Conclusions 
General considerations 
 A key objective of this analysis is to inform the general public about the challenges of 
implementing and measuring effectiveness of a community screening event.  This section is 
primarily a methodological inquiry into skin cancer-specific and general community screening 
events directed toward that end.  As evidenced by a literature review and learned through 
experience, despite the obvious value of community screening events, they are only helpful 
insofar as they reach enough people and enough data are collected to measure their success.  It is 
important to recognize and study challenges to the design and implementation of community 
screenings for the evaluation and success of future community screening events.  
 All things considered, we can confidently assume that community screening events will 
continue to be hosted under the assumption that they have some inherent, implicit value.  What 
we cannot assume, however, is that some consistent evaluative strategy for these events will be 
developed.  If such a strategy is not employed, screening events will continue to take place 





 Based on analysis of these small-scale skin cancer screening events hosted by the PDMMF, 
we are better able to think about whether conducting free, public skin cancer screening events 
can enhance our understanding of the overall value of community screening events.  The 
screening in Elon, NC on February 1, 2018 saw the highest number of participants of any event.  
This was perhaps related to more robust advertisement than for other screenings, especially 
through use of a campus faculty email listserv.  Most screening participants were white, female, 
and between 51 and 65 years old.  More than half of screening participants have had at least one 
blistering sunburn before age 20 years old and approximately half have used indoor tanning 
equipment before.  This perhaps suggests that screening events are reaching a population of 
people that are at higher risk of skin cancer than the average population.   
 Among those participants reached by telephone for follow-up, nearly one-third had seen a 
dermatologist since their screening.  This might suggest a high percentage of reached participants 
having been referred for follow-up at the time of screening, which might explain why they paid 
attention to my attempt to reach them later by telephone.   
 Based on telephone follow-up after screenings, well over half of participants surveyed 
reported demonstrating all sun-protective behaviors.  Most participants were aware that non-
melanoma skin cancer is the most commonly diagnosed cancer in the US.  Most participants 
heard about screenings through email or newsletter.  The screening in Elon, which accounted for 
a large proportion of participants, was advertised robustly through campus email threads.  
Approximately one-third of participants had never seen a dermatologist prior to the screening, 
perhaps suggesting some important barriers to care.  The most commonly suspected and most 




revealed diagnostic confirmation of four skin cancers and two precancerous AKs. 
 
Strengths and limitations 
 One strength of this study is that investigators had access to people in real-life situations 
through pre-planned community skin screening events.  Data collection through surveys is a 
relatively user-friendly method for both researcher and respondent.  Also, cohort studies 
generally involve less measurement error, can assess multiple outcomes, and can provide 
incidence estimate (Powell, 2018; Schenck, 2018).  Another advantage of this study is that 
analysis was based on data collected for the purpose of this study alone, and none other, so 
perhaps the data are of higher quality relative to their intended purposes.  
 
 Old vs. new AAD forms. 
 Halfway through the study period, the standardized AAD screening forms changed slightly 
in format and question content.  In response, I had to adapt research protocol slightly to start 
using the new screenings forms.  The result was that data derived from certain AAD screening 
form questions were excluded from the analysis if the question was present on the old but not the 
new screening form.  This choice prevented a significant amount of missing data for certain 
questions.   
 
 Study design. 
 Perhaps the most notable disadvantage of this type of observational study design is lack of 
a control group.  Without a control group, there is no standard for comparison and it is unclear 




study has less statistical validity.  A solution to this might be creation of a control group.  A 
normed comparison contrast could also be created by using statistics from the same population 
with similar experiences as the exposure group.  An alternative is using secondary source 
contrasts, through which the researcher creates data for the comparison, or a comparison group 
could be constructed using a historical control group similar to the exposure group (Powell, 
2018; Schenck, 2018). 
 This type of study is relatively subjective and time-consuming.  Also, it relies on studying 
whomever just happens to attend skin screening events.  In effect, this type of study may be 
subject to healthy-user bias: individuals who are more health conscious are more likely to seek 
out a skin screening, and seek follow-up if instructed.  The cohort aspect of this study means that 
larger sample sizes and longer follow-up period may be required for more valid results.  The 
cross-sectional piece of this study introduces the disadvantages of little information about timing 
of exposure to risk factors and onset of skin cancer (Powell, 2018; Schenck, 2018). 
 Survey data are subject to recall bias and also bias inherent in self-reported, subjective 
data.  It is important to know if people can accurately recall visits with a dermatologist and the 
level of reliability, or whether participants would give the same answer if you asked them again.  
Another important limitation of data collection by surveys is missing data due to the inability to 
reach 100% of participants by telephone (Powell, 2018; Schenck, 2018). 
 
 Data collection. 
 A potential limit of paper-and-pencil surveys is the inability to “probe” and evaluate 
context as one would be able to in an interview setting.  Also, it is sometimes difficult to achieve 




questions that are maximally clear, simple, neutral, include a timeframe, and provide exhaustive 
answer choices.  In this study, some participants were confused by the wording of some survey 
questions.  It is important in designing a good survey to use clean formatting and to provide 
explicit instructions, including how to handle skipping, which was not done in this case. 
 
Statistical validity of conclusions. 
There is a risk of having inadequate statistical power by not collecting data for enough 
screening participants. Although 216 is a relatively high number of screening participants, more 
participants would have increased power of the study.  We could have hosted more frequent, 
larger screenings to reach a higher N of cases.  Inadequate or uneven implementation of the 
intervention might also be a threat because different health care providers administered each of 
the skin screenings.  A solution would be to mandate that the same individual provider do all the 
screenings (Powell, 2018; Schenck, 2018). 
 
Internal validity. 
Uncertain temporality, or determining whether the causal screening event came before 
the effect, early detection/new diagnosis of skin cancer, might threaten internal validity.  This 
could have been minimized by surveying or interviewing participants about variables or 
influences other than attending the screening, that may have led to their getting a biopsy.  History 
may also threaten internal validity.  Again, an example might be some external event prompting 
individuals to seek dermatology care with biopsy. This type of threat could also have been 






We cannot be certain that screening participants in the study were the same as the 
hypothetical control, normed comparison, or secondary source contrast group described above.  
Study setting and resources might also influence the rates of new skin cancer diagnoses.  For 
example, ability to pay for biopsies and geographic barriers to accessing a dermatologist for a 
biopsy of suspicious lesions might differ among participants.  Again, these could have been 
assessed and possibly controlled for by asking participants about them  (Powell, 2018; Schenck, 
2018). 
 
Benefits to participants and/or society 
This study will contribute to generalizable knowledge by providing some metrics by 
which the effectiveness of free public skin cancer screenings can be measured. Specifically, 
participant follow-up data after screenings (e.g. positive biopsy rates) are helpful to determine 
the magnitude of effect that screenings have on skin cancer epidemiology.  Direct benefit to the 
participant includes potential for detection of a skin cancer that would not otherwise have been 
diagnosed, potentially sparing future morbidity and mortality. In addition, through educational 
efforts, participants learn to have an informed, keen eye for future skin cancers that may arise 
(Powell, 2018; Schenck, 2018). 
Risks of harm 
A participant who is told that a skin lesion looks suspicious for cancer may 
understandably suffer emotional distress. This was minimized by providing participants with 
adequate resources for scheduling close follow-up if further diagnostic measures or treatment 




participant data were de-identified. (Powell, 2018; Schenck, 2018). 
Ethical considerations and future research  
Some contend that skin screenings are a way for dermatologists to acquire more business.  
Others think of screenings as a great way for dermatologists to engage with the community, raise 
awareness, and promote early detection of skin cancer.  Skepticism has arisen out of concern 
about the benefits and harms of screening programs in general.  Skin cancer screenings derive 
support from an ethical perspective based on three guiding principles: utilitarianism, justice, and 
deontology.  The utilitarian approach relies on outcome data and is founded upon actions that 
bestow the greatest good for the highest number of people.  The justice-based proposition 
promotes even distribution of resources to afford access to care for traditionally underserved 
populations.  The deontology debate represents the idea of screenings as an opportunity for 
providers to foster strong relationships with patients.  Despite the fact that all of these approaches 
individually have merit, the general sentiment toward skin cancer screenings remains very 
mixed.  It is incumbent upon all of us to study whether free skin screenings have a positive 
influence on the community and save lives.  Ultimately, much more research is needed on 
outcomes and effectiveness of skin cancer screening.  Ideally, follow-up data will be collected 
and analyzed on a much larger scale, such as the entire 30-year history of AAD screening events 
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Figures & Tables 
 
Figure 1.  Number of skin screening events hosted by the Polka Dot Mama Melanoma 



























Figure 2. Presumptive diagnoses in the Polka Dot Mama Melanoma Foundation’s skin cancer 





























Figure 3. Answers to a poll asking participants to identify what they think is the most commonly-
diagnosed cancer.  Answers were obtained through in-person surveys before screenings (n = 141, 
Fig 3A) and telephone follow-up calls after screenings (n = 76, Fig 3B). 
 
3A. In-Person surveys 
 
 









Table 1. Polka Dot Mama Melanoma Foundation skin cancer screening program demographics 













































 No. of screening participants (%) 
Sex  
   Female 133 (61.6) 
   Male 83 (38.4) 
Age  
   <21 2 (0.9) 
   21-35 59 (27.3) 
   36-50 63 (29.2) 
   51-65 70 (32.4) 
   66-75 16 (7.4) 
   76+ 6 (2.8) 
Race  
   Asian 14 (6.5) 
   Black 11 (5.1) 
   Hispanic 8 (3.7) 
   Mixed 7 (3.2) 
   Other 1 (0.5) 




Table 2. Sun-protective behaviors for Polka Dot Mama Melanoma Foundation skin cancer 
screening program participants between August 1, 2017 and May 9, 2018 (n = 186). 
 
 No. of screening participants (%) 
Personal history of skin cancer 19 (10.3) 
Recently changing moles 73 (39.3) 
Frequency of sunscreen use   
   Always 72 (38.7) 
   Sometimes 91 (48.9) 
   Rarely 13 (7.0) 
   Never 10 (5.4) 
Frequency of wearing sun-protective clothing (hats, sunglasses, etc.)   
   Always 25 (13.4) 
   Sometimes 90 (48.4) 
   Rarely 31 (16.7) 
   Never 40 (21.5) 
Mean number of blistering sunburns before age 20 years old  
   0 12 (6.4) 
   1-3 101 (54.3) 
   4-6 32 (17.2) 
   7-10 19 (10.2) 
   10+ 20 (10.8) 
   Unsure 2 (1.1) 
Number of times used indoor tanning equipment  
   0 94 (50.5) 
   1-4 29 (15.6) 
   5-10 23 (12.4) 
   11-20 12 (6.5) 
   21-30 14 (7.5) 



















Table 3.  In-person survey results for Polka Dot Mama Melanoma Foundation skin cancer 
screening program participants between August 1, 2017 and May 9, 2018 (n = 141). 
 
 No. of screening participants (%) 
Sex  
   Female 86 (61.0) 
   Male 55 (39.0) 
How did you hear about the screening?   
   Advertisement 8 (5.7) 
   Email/newsletter 40 (28.3) 
   Facebook 19 (13.5) 
   Family or friend 26 (18.4) 
   TV/Cable news 1 (0.7) 
   Website/Search engine 19 (13.5) 
   Other 28 (19.9) 
Ever seen a dermatologist?  
   Yes 97 (68.8) 
































Table 4.  Telephone follow-up survey results for Polka Dot Mama Melanoma Foundation skin 
cancer screening program participants between August 1, 2017 and March 27, 2018 (n = 75, 
34.7% of total 216 screened). 
 
 No. of screening participants (%) 
Seen a dermatologist since the screening?  
   Yes 21 (28.0) 
   No 54 (72.0) 
Been using sunscreen?  
   Yes 55 (73.3) 
   No 20 (26.7) 
Average SPF 36.7  13.5 
Seek shade?  
   Yes 50 (66.7) 
   No 25 (33.3) 
Wear sun-protective clothing since screening?  
   Yes 62 (82.7) 
   No 13 (17.3) 
Any sunburns or tans since screening?  
   Yes 17 (22.7) 
   No 58 (77.3) 
Perform skin self-exams since screening?  
   Yes 44 (58.7) 
   No 31 (41.3) 
Spoken with family or friends about sun-
protective behaviors since screening? 
 
   Yes 49 (65.3) 






















Table 5.  Skin screening results for Polka Dot Mama Melanoma Foundation skin cancer 
screening program participants reached by telephone follow-up between August 1, 2017 and 
March 27, 2018. 
 
Total participants screened 216 
   Number of participants referred for biopsy 52 (24.1) 
   Number of participants successfully contacted for telephone follow-up 75 (34.7) 
Number of participants referred for biopsy among those contacted for follow-up 12 (16.0) 
   Participants biopsied among those referred 8 (66.7) 
      Confirmed diagnoses among participants biopsied  
         Benign lesion 7 
         BCC 3 
         AK 2 
         SCC 1 



































Appendix I: Methods, results, surveys, dates & locations of screenings 
(Note: A significant portion of this Appendix was taken directly from the study’s IRB application) 
 
Study design 
 This is an observational, quasi-experimental study both cross-sectional and retrospective in 
nature.  This type of study design is simple with no control, one group, post-test only.  It does not 
compare outcomes against another treatment arm. 
 
Data collection        
Data was collected through in-person and telephone follow-up surveys administered 
throughout the study period. Prior to each screening, participants completed two forms: a 
standardized AAD form and in-person study survey.  The standardized AAD form includes 
information primarily about demographics, health care access/services, and skin cancer risk 
factors.  It also contains a section for obtaining consent and permission to release medical 
information in case of a suspicious lesion.  The study survey (found in Appendix I) is IRB-
approved, voluntary, and anonymous.  It requested information about how the participant 
discovered the screening and a general knowledge question.  Then, participants completed a 
screening skin examination by a local provider recruited on a volunteer basis. The provider 
screened participants by visual examination meanwhile recording results and presumed 
diagnoses, including AK, DN, CN, BCC, SCC, melanoma, and lesion-NOS.  The physician then 
determined and recorded whether a referral was made.  Screenings were non-invasive and did 
not involve any biopsies.  Participants with concerning lesions were advised to follow-up with 




provided with names and contact information for local dermatologists.  Participants screened 
during the nine-month period August 1, 2017 and May 9, 2018 were contacted by telephone at 
least six weeks after their screening to complete a survey and determine follow-up status.  If 
participants could not be reached upon first contact, a voicemail was left following the attached 
script. We did not have the capacity to link before- and after-screening surveys because we did 
not collect any identifying information.  Standardized screening forms were returned to the AAD 
for central tracking. 
 
Data management 
Participants could voluntarily withdraw at any time and we did not use any data collected 
for participants that declined to participate.  All investigators only kept the research data on their 
password-protected computer login account.  Any transfer of data between investigators used 
encrypted e-mail.  Once data were collected, it was not possible to identify participants because 
the surveys did not contain any identifying information. A spreadsheet kept by the principal 
investigator linked dummy identifier numbers to participant identifiers was deleted at the 




As an observational study with participant contact through a survey and skin exam, there 
were no foreseeable safety concerns. The primary investigator monitored for any safety concerns 






Screenings took place at the following locations: NCDA, DLC, Elon University, Duke 
University, Cary Senior Center, Charles Drew Community Health Center (Burlington, NC), 
Optimum Healthcare IT (Jacksonville, FL), and Lenovo (Research Triangle Park).  Screenings 
were provided by a local dermatologist, nurse practitioner, or physician’s assistant.  The 
dermatologists (all M.D.s) included: Elizabeth Ju (EJ), Vikas Patel (VP), Health Lampel (HL), 
David Kowalski (DK), David Dasher (DD) and Stephanie Carstens (SC).  The physician’s 
assistant was Leighanne McGill, PA-C (LM) and the nurse practitioner was Karlee Wagoner 
(KW).  See Appendix I for more screening details.   
 
Recruitment 
All investigators helped to recruit participants in-person, on-site during screening events 
as representatives of the PDMMF. The study was described to them and they were asked for 
verbal consent.  Participants were also recruited by word-of-mouth at screening locations 
throughout North Carolina, including neighborhoods, public establishments, and corporations. 
Screening events were planned for locations and times to maximize chances of recruiting at least 
25 participants.  We did not in any way target or recruit UNC employees, but we cannot say that 
someone who works for UNC did not show up. Because we did not collect any identifying 
information, we do not know where any participants work. 
 
Sample and participant selection 
 All participants were attendees of a PDMMF free, public skin cancer screening.  The only 




older who attend free skin cancer screenings hosted by the PDMMF were included.  There was 
no discrimination or bias for participation based on gender or ethnicity.  By attending multiple 
screening events, I estimated prior to beginning that I could recruit as many as 325 participants. 
On average, about 25 participants were expected at each screening. 
 
Human Subject Protection and Institutional Review Board Approval 
 As the investigator, I gained approval for analysis of de-identified screening data through 
the UNC-Chapel Hill Institutional Review Board. I have followed all standards set forth by the 
UNC-CH IRB in order to protect participant privacy and information. 
 
Variables 
 The following identifiers were collected: names, birth dates, telephone numbers, email 
addresses, mailing address.  Other variables were responses to in-person and telephone follow-up 
surveys as shown in Appendix I.  All identifiers were stored with the research data in the same 




 We performed statistical analysis using Stata/MP 15.0 (StataCorp, College Station, TX).  
First, summary statistics were calculated for basic demographic information as summarized in 
Table 1.  Next, summary statistics were computed for responses to both in-person and telephone 
surveys.  Summary statistics were also computed to describe screening follow-up results, such as 




biopsies and specific diagnoses.  Before and after analyses were based on aggregate rather than 
individual-level results as we did not have the capacity to link before- and after-screening 
surveys, because we did not collect any identifying information. 
 
Participant contact and privacy 
 No limited waiver of HIPAA authorization was requested and ongoing access to PHI was 
not needed beyond identification of participants as addressed above.  Participants were each 
contacted two times total for a total duration of approximately 15 minutes of participation.  The 
first contact was for the survey and screenings, which took approximately 10 minutes. The next 
contact was a follow-up phone call, which lasted no longer than 5 minutes.  Screenings and data 
collection were conducted both in private clinic settings and in the mobile screening unit, which 
parked in public locations and on-site corporations. Follow-up phone calls were made by the 
principal investigator and research assistant.  Phone calls were made in privacy where other 
people were not able to hear the conversation. Participant names were confirmed before 
discussing follow-up.   
 Consent was obtained at the time of screening. For participants who were called, consent 
was obtained verbally over the phone by study personnel listed on the IRB. Participants were 
informed that they may decline to participate without negative repercussions.  We requested a 
waiver of written (signed) documentation, as consent was incorporated into the survey itself and 
verbal consent was obtained in-person and by phone.  This is because the research presented no 
more than minimal risk of harm to participants and involved no procedures for which written 
consent was normally required outside of the research context. The screenings, not considered by 




waiver applied to all participants as the consent statement is incorporated in the survey itself.  
Participant phone numbers for contact by follow-up telephone survey were obtained from AAD 
screening form (see Appendix I) only to contact participants, then their responses to survey 
questions were completely de-identified (i.e. without any identifying information). After the 





































Screening forms and surveys 














































“Hello, this message is for Mr./Ms. _(name)_.  My name is _______ and I met you at a 
community health skin screening event back in _(date)_ when you kindly agreed to complete one 
of my surveys.  I am calling to ask few quick follow-up questions.  Please call me back at 336-






Date Location Provider 
8/1/17 NCDA EJ 
9/5/17 NCDA EJ 
11/7/17 NCDA EJ 
12/5/17 NCDA EJ 
12/18/17 DLC KW 
1/29/18 DLC KW 
2/1/18 Elon DD 
2/4/18 Duke KW & VP 
2/6/18 NCDA EJ 
2/26/18 DLC KW & LM 
3/6/18 NCDA EJ 
3/15/18 Cary HL 
3/16/18 Charles Drew DK 
3/23/18 Optimum IT SC 
3/27/18 DLC KW & LM 
4/30/18 DLC KW 





























Appendix II: Limited systematic review: Comparison of outcomes for cutaneous melanoma 
treated with Mohs micrographic surgery and wide local excision 
(Note: This was taken directly from my final assignment for PUBH 702) 
I. Introduction1-9 
a. Rationale1-8 
i. Although Mohs Micrographic Surgery (MMS) has been used successfully to treat both 
in situ and invasive cutaneous melanoma, standard of care and recommended treatment 
is wide local excision (WLE).  Compared to MMS, however, WLE provides incomplete 
examination of tumor surgical margins.  MMS assesses 100% of tumor margins, 
meanwhile WLE assesses less than 1%.1,4,5  Complete margin assessment has been 
shown to decrease local recurrence rates for melanoma in situ, especially lentigo 
maligna.1,4,5,6  Past studies have estimated local recurrence rates following conventional 
treatment with WLE of up to 13% for the head and neck region and ~3% for the trunk 
and extremities.1,2,3  Since surgical excision without adequate margin control increases 
the likelihood of recurrence, a review of evidence is needed to evaluate recurrence rates 
and mortality in patients with melanoma treated with MMS.  Studies have shown non-
inferior disease specific survival for Mohs micrographic surgery treatment of invasive 
melanoma when compared to wide local excision with conventional histologic 
evaluation of margins.1,4 In the future, this review could provide further evidence in 
support of or against MMS melanoma and propose an update to the MMS Appropriate 
Use Criteria (AUC).1-8 
ii. Guidelines by the American Academy of Dermatology and National Comprehensive 




situ, but there is no recommendation on the role of MMS for invasive melanomas. In 
practice, however, MMS is also being used to treat invasive melanoma for complete 
margin assessment, and large published case series have demonstrated the efficacy of 
such treatment.1,7,8 
iii. As MMS is currently not standard of care for the treatment of melanoma, national 
utilization patterns vary among dermatologic surgeons.  Past literature has shown low 
recurrence rates and high disease free survival for MMS, demonstrating it as an 
effective treatment for invasive melanoma.1  
b. Objective: The objective of this review is to evaluate the effectiveness of Mohs 
micrographic surgery on the mortality and recurrence rates in patients with cutaneous 
melanoma when compared with compared with wide local excision.  As such, this review 
seeks to address the two following key questions: 
i. How do recurrence rates (local and distant/metastatic) after MMS compare to those 
after WLE? 
ii. How do mortality rates after Mohs Micrographic Surgery (MMS) compare to those 
after conventional treatment with wide-local excision (WLE)? 
II. Methods9,10,11-14 
a. Protocol and registration 








b. Eligibility criteria  
 
 Inclusion Exclusion 
Population • Patients of any age or gender 
• Established diagnosis of situ or invasive 
cutaneous melanoma of any anatomic location 
confirmed histologically, clinically, or both by 
a trained healthcare professional. 
• Suspected or unconfirmed diagnosis of 
cutaneous melanoma. 
• Diagnosis of other conditions, lesions, or 
neoplasms such as non-melanoma skin 
cancers. 
Intervention • MMS as a treatment for cutaneous melanoma. • Other treatment modalities including, but not 
limited to curettage and electrodessication, 
radiotherapy, topical 5-fluorouracil and 
imiquimod immunotherapy. 
Comparison • Conventional and recommended treatment with 
WLE (including historical control rates). 
• Other treatment modalities including, but not 
limited to curettage and electrodessication, 
radiotherapy, topical 5-fluorouracil and 
imiquimod immunotherapy. 
Outcomes • Primary: proportion and rates of recurrence 
(local and distant/metastatic). 
• Secondary: overall and disease-specific 
mortality rates. 
• All time frames for mortality and recurrence 
will be reported. 
• Benefits and harms to patient 
• Cost-effectiveness  
• Utilization patterns among Mohs surgeons 
• Quality of life measures 
• Adverse event or complication frequency 
• Worry, anxiety, or self-consciousness  
Timing • 1969 to present (MMS was known as early as 
1969, but not fully-implemented until 1985).14 
• None 
Setting • Dermatology/Mohs surgery settings in the US 
and internationally. 
• Non-medical/non-dermatologic setting 
Study 
Design 
• Studies using MMS in one group and at least 
one other control/comparator group (including 
historical). 
• Experimental designs (RCTs, clinical-
controlled trials, and quasi-experimental) 
• Observational studies (longitudinal prospective 
cohort, retrospective cohort, case-control) 
• Epidemiological studies (cross-sectional) 
• All other study designs (letters, journal 
articles, case studies/series, etc.) 
• Non-English studies 
 
c. Information sources 
i. The following databases were searched for the time period January 1, 1969 to present: 
PubMed, Embase, Cochrane Library, and ClinicalTrials.gov.  Date of the last search of 





d. Search methods 
i. Electronic searches 
1. The search was designed to identify both published and unpublished studies.  An 
initial search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov was 
performed using the keywords found in appendices.  Search restrictions are 
detailed above in table of eligibility criteria.  Of note, no language restriction was 
used. 
ii. Other resources 
1. Electronic searches were supplemented with eligible articles recommended by the 
reviewer and personal files, including articles “in press.”  Reference lists of 
included studies were also manually searched to find additional articles.  No 
journals or conference proceedings were searched manually. 
e. Study selection 
i. The process of study selection first entailed merging results into Mendeley.  Studies 
retrieved from the search were automatically compared by author name, date of study, 
institution location/name, and journal to remove duplicates.  Then, screening of title 
and abstracts was completed to identify and exclude irrelevant studies.  Studies were 
placed into one of three categories – yes, no, or maybe – for inclusion.  Full texts were 
retrieved for all articles in the yes and maybe categories to review for potentially 
relevant studies.  If necessary, further information was obtained by contacting authors 
of studies in the maybe category.  Finally, the solo reviewer determined if these studies 
met inclusion criteria by dividing them into include or exclude.   




i. Data was extracted from papers included in the review by one reviewer using the 
standardized data extraction tool in Covidence Software.10 Data sought included details 
about populations, interventions, comparator, mortality, recurrence, and study design.  
Data extracted specifically included the following: 
1. Identification information 
a. Study details: sponsorship source, country, setting, comments 
b. Author’s contact details: name, institution, email, address 
c. Additional data 
2. Methods: design, group 
3. Population: inclusion criteria, exclusion criteria, group differences, baseline 
characteristics 
4. Interventions and comparisons 
5. Outcomes  
ii. When possible and appropriate, study authors were contacted in the case of missing 
data.  Authors were given eight weeks to respond, after which the review proceeded 
with missing data. 
g. Risk of bias in individual studies 
i. Studies that met inclusion criteria after full-text review were assessed individually by 
one reviewer for bias and methodological quality using the Cochrane Risk of Bias Tool, 
a standardized critical appraisal instrument.   
ii. Risk of bias level (low, medium, or high), along with judgment comments, was 




iii. Domains included sequence generation (not applicable), allocation concealment (not 
applicable), blinding (participants, personnel, outcome assessors), incomplete outcome 
data, selective outcome reporting, and other.  Other sources of bias could include early 
stop to the study due to some data-related issue, study design-related bias, imbalance at 
baseline, and/or illegitimacy.  
iv. Some studies deemed high risk of bias were excluded from analysis. 
h. Summary measures  
i. Reported outcome measures were determined primarily by level of measurement and 
study design.  All outcomes were expressed as rates, proportions, odds ratios, risk 
ratios, or means.   
i. Synthesis of results 
i. Narrative text and tables were used for presentation of data.  This review’s unit of 
analysis encompassed all studies meeting specified inclusion criteria. 
ii. Heterogeneity among studies was first assessed by reviewing the full text articles to 
recognize any clear differences in methodology.  Then, I2 was measured for formal 
approximation of discrepancy between studies.  
iii. If enough homogeneity among trials existed, results were pooled and synthesized using 
a meta-analysis random-effects model for both the primary and secondary outcome 
measures.  If significant heterogeneity was present among studies, results were 
presented using a descriptive overview. 
j. Risk of bias across studies 





k. Additional analyses 
i. Sensitivity analyses were conducted to determine the effect of excluding high-bias 
studies of low methodological quality. 
III. Results9  
a. Study selection10 
i. Figure 1.  Results from searching for studies for inclusion in the review.  
 
ii. Electronic and manual searches retrieved 1,014 total titles and abstracts.  A total of 44 
results were identified as duplicates and removed accordingly to leave 967 studies for 




irrelevant to the scope of the review were removed.  After review of titles and abstracts, 
938 were determined to be irrelevant and excluded due to titles and/or abstracts that did 
not satisfy inclusion criteria.  At this point, 29 full-text studies were left for eligibility 
assessment.  Upon full-text review, 23 studies were excluded for reasons below to leave 
10 studies that met all eligibility criteria and were included in the systematic review: 
1. Wrong intervention (8 studies): staged excision or “slow Mohs” technique 
2. Wrong or absent comparator (5 studies) 
3. Wrong outcomes (4 studies): quality of life, cost-effectiveness outcomes, etc. 
4. Wrong study design (4 studies): letters, journal articles, and case studies/series 
5. Wrong indication (2 studies): non-melanoma skin cancer, digital or subungal 















b. Study characteristics 
Source No. of Lesions 
Treated/Patient 
Age, y 
Study design Follow-up 
Period, mo 
Local Recurrence Rate, 
% (95% CI or  SE) 
Metastatic recurrence 
Rate, % (95% CI or  SE) 
Disease-specific 
survival, mo 
Bricca et al, 
2005 
      
MMS 625/67.9 (mean, 




58 (mean) 0.3  0.2 3.6  0.9 96.1  1.0 
WLE Not available  42 (mean) See Table III See Table IV See Figure 3 
Chin-Lenn et 
al, 2013 
      
MMS 60/69.4 Retrospective 
chart review 
47.5 (median) 6.2 (p = 0.58) 8.8 (p = 0.37) 92.4 (p =0.59) 
WLE 91/66.3  49 (median) 7.9 (p = 0.58) 18.8 (p = 0.37) 82.8 (p =0.59) 




    
MMS 123/66.48 (mean)  42.4 (mean) 1.63 (0.20 – 5.75) 0 100 
WLE Not available  Not available 7.5 (historical control) Not available Not available 




    
MMS 577/60 (mean, in 
situ), 65 (mean, 
invasive) 
 34.2 0.34  Not available Not available 
WLE Not available 
 
 See study Table 
IV 
See study Table IV Not available Not available 










MMS 277/64 (mean)  103.2 (mean) 1.1 (5-year, p = 0.07) 
 
1.8 (overall) 
Not available 78 
WLE 385/58.5 (mean)  Not available 4.1 (5-year, p = 0.07) 
 
5.7 (overall) 
Not available 73.2 




    
MMS 535/64.5 (mean in 
situ), 60.0 (mean, 
invasive) 
 60 0.5 1 +/- 1 (in situ), 11 +/- 2 
(invasive) 
99 +/-1 1 (in situ), 
93 +/- 1.4 
(invasive) 




c. Risk of bias within studies 
d. Results of individual studies 
e. Synthesis of results 
f. Risk of bias across studies 
g. Additional analysis 
IV. Discussion9  
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